Other: pigmentation of the skin and conjunctiva, cornea and sclera discoloration, reduced tolerance to high temperatures effects (up to the development of heat stroke), melasma.
Local reactions: infiltration can npp deca occur when administered intramuscularly, in contact with the liquid form on the skin – contact dermatitis.
Overdose (intoxication) drug
Symptoms: areflexia and hyperreflexia, blurred vision, cardiotoxic effects (arrhythmia, heart failure, decreased blood pressure, shock, tachycardia, changes in the complex the npp deca, ventricular fibrillation, cardiac arrest), neurotoxic effects, including agitation, confusion , convulsions, disorientation, lethargy, stupor or coma; dilated pupils, dry mouth, hyperpyrexia or hypothermia, muscle rigidity, vomiting, pulmonary edema and respiratory depression.
Treatment – symptomatic: for arrhythmia – intravenous , in heart failure – cardiac glycosides, with marked decrease in blood pressure – in / in a liquid or vasopressor agents such as norepinephrine, phenylephrine (to avoid purpose of alpha- and beta-agonists such as epinephrine as possible paradoxical decrease in blood pressure by blocking the alpha-adrenoceptor trifluoperazine), in convulsions – diazepam (barbiturates avoided due to possible subsequent npp deca depression and respiratory), parkinsonism – difeniltropin diphenhydramine. Control functions of the cardiovascular system during at least 5 days, the central nervous system, respiration, body temperature measurement, psychiatric counseling. Dialysis is ineffective.
Interaction with other drugs
With simultaneous application triftazin with other drugs, have a depressing effect on the central nervous system (funds for general anesthesia, opioids, ethanol (alcohol) and containing its drugs, barbiturates, tranquilizers, and others.) May increase CNS depression as well as respiratory depression;
undesirably prolonged combination with analgesics and antipyretics – may develop hyperthermia;
tricyclic antidepressants, maprotiline, or monoamine oxidase inhibitors – increase the risk of neuroleptic malignant syndrome; with anticonvulsants – perhaps lowering the seizure threshold; with preparations for the treatment of hyperthyroidism – increased risk of agranulocytosis; with other drugs causing extrapyramidal reactions – may increase the frequency and severity of extrapyramidal disorders;
with antihypertensive drugs – can be severe orthostatic hypotension; with ephedrine – may weaken the vasoconstrictor effect of ephedrine. When treating triftazin avoid administration of epinephrine (adrenaline), since distortion may effect epinephrine, which can lead to a drop in blood pressure. Antiparkinsonian effect of levodopa is reduced due to the blocking of dopamine receptors. Triftazin can suppress the effect of amphetamines, clonidine, guanethidine. Triftazin enhance the anticholinergic effects of other drugs, and the antipsychotic effect of neuroleptics may be reduced.
In an application with triftazin prochlorperazine may come a prolonged loss of consciousness.
Combination with lithium therapy increases the risk of extrapyramidal complications. Triftazin can mask some of the manifestations of ototoxicity (tinnitus, vertigo), ototoxic drugs providing an action. Other hepatotoxic drugs increase the risk of hepatotoxicity. Antacids containingnpp deca reduce the absorption triftazine.